Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease —Reply

In Reply Mr Han raises an important point regarding the use of TCIs, which are labeled for use in atopic dermatitis, to treat HHD. The FDA issued a black box warning of a possible association between TCI use and the development of cancer (lymphoma and skin) based on case reports and animal studies, a warning not supported by the American Academy of Dermatology. Most of these animal studies demonstrated an increased risk of malignancy after administration of systemic or topical calcineurin inhibitors in doses far exceeding those used by humans.
Source: JAMA - Category: General Medicine Source Type: research